FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002127959> ?p ?o ?g. }

• W2002127959 endingPage "18" @default.
• W2002127959 startingPage "5" @default.
• W2002127959 abstract "AIMS To evaluate the pharmacokinetics, safety and tolerability of single and multiple oral doses of maraviroc in healthy volunteers. METHODS Three double‐blind, placebo‐controlled, dose‐escalation studies with either single or multiple doses of maraviroc were conducted in healthy volunteers. Plasma and urine samples were collected to investigate the pharmacokinetics of maraviroc and evaluate any changes with respect to dose and duration/frequency of dosing. Safety and toleration of maraviroc were also assessed. RESULTS Maraviroc is rapidly absorbed following oral administration, and plasma T max is achieved within 0.5–4.0 h postdose. Steady‐state plasma concentrations are achieved after 7 consecutive days of dosing. Although the pharmacokinetics of maraviroc is nonproportional over the dose range studied (3–1200 mg), the degree of nonproportionality is small at clinically relevant doses. Renal clearance is approximately 10–12 l h −1 and appears unaffected by increasing maraviroc doses. Maraviroc does not significantly modulate the activity of CYP2D6 or CYP3A4 at clinically relevant doses. There were no serious adverse events in any of these studies, and doses up to 900 mg were generally well tolerated, with postural hypotension being the dose‐limiting event. There was no pattern or dose relationship observed with maraviroc with regard to laboratory abnormalities, including hepatic transaminases. No clinically significant increases in QTc were noted at clinically relevant doses. CONCLUSIONS Maraviroc is absorbed into the systemic circulation and reaches steady state by day 7 of multiple dosing. It does not significantly influence the activity of major drug‐metabolizing enzymes and is well tolerated at clinically relevant doses, with most adverse events being mild or moderate." @default.
• W2002127959 created "2016-06-24" @default.
• W2002127959 creator A5002243618 @default.
• W2002127959 creator A5019219577 @default.
• W2002127959 creator A5044994717 @default.
• W2002127959 creator A5056696602 @default.
• W2002127959 creator A5061029367 @default.
• W2002127959 creator A5062304028 @default.
• W2002127959 creator A5079055631 @default.
• W2002127959 date "2008-03-10" @default.
• W2002127959 modified "2023-10-17" @default.
• W2002127959 title "Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers" @default.
• W2002127959 cites W1986574361 @default.
• W2002127959 cites W1993091182 @default.
• W2002127959 cites W1998202799 @default.
• W2002127959 cites W1999048558 @default.
• W2002127959 cites W2017255942 @default.
• W2002127959 cites W2035377904 @default.
• W2002127959 cites W2039244520 @default.
• W2002127959 cites W2046134251 @default.
• W2002127959 cites W2090126383 @default.
• W2002127959 cites W2103160360 @default.
• W2002127959 cites W2117378263 @default.
• W2002127959 cites W2132333355 @default.
• W2002127959 cites W2149653091 @default.
• W2002127959 cites W2326093178 @default.
• W2002127959 doi "https://doi.org/10.1111/j.1365-2125.2008.03130.x" @default.
• W2002127959 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2311414" @default.
• W2002127959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18333861" @default.
• W2002127959 hasPublicationYear "2008" @default.
• W2002127959 type Work @default.
• W2002127959 sameAs 2002127959 @default.
• W2002127959 citedByCount "78" @default.
• W2002127959 countsByYear W20021279592012 @default.
• W2002127959 countsByYear W20021279592013 @default.
• W2002127959 countsByYear W20021279592014 @default.
• W2002127959 countsByYear W20021279592015 @default.
• W2002127959 countsByYear W20021279592016 @default.
• W2002127959 countsByYear W20021279592017 @default.
• W2002127959 countsByYear W20021279592018 @default.
• W2002127959 countsByYear W20021279592019 @default.
• W2002127959 countsByYear W20021279592020 @default.
• W2002127959 countsByYear W20021279592022 @default.
• W2002127959 countsByYear W20021279592023 @default.
• W2002127959 crossrefType "journal-article" @default.
• W2002127959 hasAuthorship W2002127959A5002243618 @default.
• W2002127959 hasAuthorship W2002127959A5019219577 @default.
• W2002127959 hasAuthorship W2002127959A5044994717 @default.
• W2002127959 hasAuthorship W2002127959A5056696602 @default.
• W2002127959 hasAuthorship W2002127959A5061029367 @default.
• W2002127959 hasAuthorship W2002127959A5062304028 @default.
• W2002127959 hasAuthorship W2002127959A5079055631 @default.
• W2002127959 hasBestOaLocation W20021279592 @default.
• W2002127959 hasConcept C109650736 @default.
• W2002127959 hasConcept C112705442 @default.
• W2002127959 hasConcept C126322002 @default.
• W2002127959 hasConcept C12823836 @default.
• W2002127959 hasConcept C13373296 @default.
• W2002127959 hasConcept C142724271 @default.
• W2002127959 hasConcept C170493617 @default.
• W2002127959 hasConcept C197934379 @default.
• W2002127959 hasConcept C203014093 @default.
• W2002127959 hasConcept C204787440 @default.
• W2002127959 hasConcept C22979827 @default.
• W2002127959 hasConcept C27081682 @default.
• W2002127959 hasConcept C2777288759 @default.
• W2002127959 hasConcept C2778375690 @default.
• W2002127959 hasConcept C2778899366 @default.
• W2002127959 hasConcept C3013748606 @default.
• W2002127959 hasConcept C37044404 @default.
• W2002127959 hasConcept C526171541 @default.
• W2002127959 hasConcept C62231903 @default.
• W2002127959 hasConcept C71924100 @default.
• W2002127959 hasConcept C98274493 @default.
• W2002127959 hasConceptScore W2002127959C109650736 @default.
• W2002127959 hasConceptScore W2002127959C112705442 @default.
• W2002127959 hasConceptScore W2002127959C126322002 @default.
• W2002127959 hasConceptScore W2002127959C12823836 @default.
• W2002127959 hasConceptScore W2002127959C13373296 @default.
• W2002127959 hasConceptScore W2002127959C142724271 @default.
• W2002127959 hasConceptScore W2002127959C170493617 @default.
• W2002127959 hasConceptScore W2002127959C197934379 @default.
• W2002127959 hasConceptScore W2002127959C203014093 @default.
• W2002127959 hasConceptScore W2002127959C204787440 @default.
• W2002127959 hasConceptScore W2002127959C22979827 @default.
• W2002127959 hasConceptScore W2002127959C27081682 @default.
• W2002127959 hasConceptScore W2002127959C2777288759 @default.
• W2002127959 hasConceptScore W2002127959C2778375690 @default.
• W2002127959 hasConceptScore W2002127959C2778899366 @default.
• W2002127959 hasConceptScore W2002127959C3013748606 @default.
• W2002127959 hasConceptScore W2002127959C37044404 @default.
• W2002127959 hasConceptScore W2002127959C526171541 @default.
• W2002127959 hasConceptScore W2002127959C62231903 @default.
• W2002127959 hasConceptScore W2002127959C71924100 @default.
• W2002127959 hasConceptScore W2002127959C98274493 @default.
• W2002127959 hasIssue "s1" @default.
• W2002127959 hasLocation W20021279591 @default.
• W2002127959 hasLocation W20021279592 @default.

• next